ninety-seven patients less than or equal to 70 years of age with previously untreated primary acute myeloblastic leukemia were randomly treated with either the dat or tad regimen : daunorubicin ( 70 mg/m2/day ) administered on days 1-3 ( dat ) or 5-7 ( tad ) of a 7-day sequence consisting of cytarabine ( 200 mg/m2/day ) and 6-thioguanine ( 200 mg/m2/day ) .
C0144442
tad regimen
C0011015
daunorubicin